ArticleBiofabrication2018
Engineering of microscale vascularized fat that responds to perfusion with lipoactive hormones.
Article in Biofabrication, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Towards Cost-Effective and Sustainable Media Formulations for Terrestrial and Aquatic Cellular Agriculture.Foods (Basel, Switzerland) · 2026Review
- Bioengineering a Patient-Derived Vascularized Lung Tumor-on-Chip Model to Decipher Immunomodulation by the Endothelium.Advanced healthcare materials · 2025Article
- Organoid-based tissue engineering for advanced tissue repair and reconstruction.Materials today. Bio · 2025Review
- Obesity-Associated Conditions Hinder Solute Drainage Function of Engineered Human Lymphatic Vessels.Cellular and molecular bioengineering · 2025Article
- Unleashing the potential of adipose organoids: A revolutionary approach to combat obesity-related metabolic diseases.Theranostics · 2024Review
- Biofabrication of engineered blood vessels for biomedical applications.Science and technology of advanced materials · 2024Review
- Article
- Adipose Cells Induce Escape from an Engineered Human Breast Microtumor Independently of their Obesity Status.Cellular and molecular bioengineering · 2023Article
- Adipose Stroma Accelerates the Invasion and Escape of Human Breast Cancer Cells from an Engineered Microtumor.Cellular and molecular bioengineering · 2022Article
- Perspectives on scaling production of adipose tissue for food applications.Biomaterials · 2022Article
- Vascularized Microfluidics and Their Untapped Potential for Discovery in Diseases of the Microvasculature.Annual review of biomedical engineering · 2021Review
- Composable microfluidic spinning platforms for facile production of biomimetic perfusable hydrogel microtubes.Nature protocols · 2021Article
- Microfluidic Biomaterials.Advanced healthcare materials · 2021Review
- From arteries to capillaries: approaches to engineering human vasculature.Advanced functional materials · 2020Article
- Tissue Engineering of the Microvasculature.Comprehensive Physiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Current methods to treat large soft-tissue defects mainly rely on autologous transfer of adipocutaneous flaps, a method that is often limited by donor site availability. Engineered vascularized adipose tissues can potentially be a viable and readily accessible substitute to autologous flaps. In this study, we engineered a small-scale adipose tissue with pre-patterned vasculature that enables immediate perfusion. Vessels formed after one day of perfusion and displayed barrier function after three days of perfusion. Under constant perfusion, adipose tissues remained viable and responded to lipoactive hormones insulin and epinephrine with lipid accumulation and loss, respectively. Adipocyte growth correlated inversely with distance away from the feeding vessel, as predicted by a Krogh-type model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.